_id
690daf9eccc777a4e85d0b19
Ticker
APDN
Name
Applied DNA Sciences Inc
Exchange
NASDAQ
Address
50 Health Sciences Drive, Stony Brook, NY, United States, 11790
Country
USA
Sector
Healthcare
Industry
Diagnostics & Research
Currency
USD
Website
https://www.adnas.com
Description
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. The company was founded in 1983 and is headquartered in Stony Brook, New York.
Last Close
2.33
Volume
19386
Current Price
2.49
Change
0.12
Last Updated
2025-11-28T12:17:29.908Z
Image
data:image/webp;base64,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
Ipo Date
2003-07-15T00:00:00.000Z
Market Cap
7258033
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Rating
3
Target Price
1.5
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
304393
Cost Of Revenue
299263
Gross Profit
5130
Operating Expenses
3699190
Operating Income
-3694060
Interest Expense
-
Pretax Income
-3647914
Net Income
-3945363
Eps
-6.897270715257212
Dividends Per Share
-
Shares Outstanding
1291465
Income Tax Expense
-
EBITDA
-3615714
Operating Margin
-1213.5824411205251
Total Other Income Expense Net
46146
Cash
4727677
Short Term Investments
-
Receivables
199047
Inventories
338723
Total Current Assets
5628902
Property Plant Equipment
845605
Total Assets
9934746
Payables
614759
Short Term Debt
334403
Long Term Debt
-
Total Liabilities
2946702
Equity
7262568
Depreciation
78346
Change In Working Capital
853585
Cash From Operations
-2816258
Capital Expenditures
10923
Cash From Investing
10077
Cash From Financing
723056
Net Change In Cash
-2083125
PE
-
PB
0.19611862085146742
ROE
-54.32462732190597
ROA
-39.71277172058551
FCF
-2827181
Fcf Percent
-9.287930405758345
Piotroski FScore
1
Health Score
34
Deep Value Investing Score
6.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
4.5
Net Net Investing Score
3.5
Quality Investing Score
2.5
Value Investing Score
5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
304393
Quarters > 0 > income Statement > cost Of Revenue
299263
Quarters > 0 > income Statement > gross Profit
5130
Quarters > 0 > income Statement > operating Expenses
3699190
Quarters > 0 > income Statement > operating Income
-3694060
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-3647914
Quarters > 0 > income Statement > net Income
-3945363
Quarters > 0 > income Statement > eps
-6.897270715257212
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
572018
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-3615714
Quarters > 0 > income Statement > operating Margin
-1213.5824411205251
Quarters > 0 > income Statement > total Other Income Expense Net
46146
Quarters > 0 > balance Sheet > cash
4727677
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
199047
Quarters > 0 > balance Sheet > inventories
338723
Quarters > 0 > balance Sheet > total Current Assets
5628902
Quarters > 0 > balance Sheet > property Plant Equipment
845605
Quarters > 0 > balance Sheet > total Assets
9934746
Quarters > 0 > balance Sheet > payables
614759
Quarters > 0 > balance Sheet > short Term Debt
334403
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
2946702
Quarters > 0 > balance Sheet > equity
7262568
Quarters > 0 > cash Flow > net Income
-3580989
Quarters > 0 > cash Flow > depreciation
78346
Quarters > 0 > cash Flow > change In Working Capital
853585
Quarters > 0 > cash Flow > cash From Operations
-2816258
Quarters > 0 > cash Flow > capital Expenditures
10923
Quarters > 0 > cash Flow > cash From Investing
10077
Quarters > 0 > cash Flow > cash From Financing
723056
Quarters > 0 > cash Flow > net Change In Cash
-2083125
Quarters > 0 > ratios > PE
-6.897270715257212
Quarters > 0 > ratios > PB
0.19611862085146742
Quarters > 0 > ratios > ROE
-54.32462732190597
Quarters > 0 > ratios > ROA
-39.71277172058551
Quarters > 0 > ratios > FCF
-2827181
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-9.287930405758345
Quarters > 0 > health Score
34
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
983374
Quarters > 1 > income Statement > cost Of Revenue
612527
Quarters > 1 > income Statement > gross Profit
370847
Quarters > 1 > income Statement > operating Expenses
3832642
Quarters > 1 > income Statement > operating Income
-3461795
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-3336120
Quarters > 1 > income Statement > net Income
-27223604
Quarters > 1 > income Statement > eps
-15.353797841729053
Quarters > 1 > income Statement > dividends Per Share
38826652
Quarters > 1 > income Statement > shares Outstanding
1773086
Quarters > 1 > income Statement > income Tax Expense
23887484
Quarters > 1 > income Statement > EBITDA
-3217450
Quarters > 1 > income Statement > operating Margin
-352.03239052486646
Quarters > 1 > income Statement > total Other Income Expense Net
125675
Quarters > 1 > balance Sheet > cash
6823260
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
689887
Quarters > 1 > balance Sheet > inventories
348866
Quarters > 1 > balance Sheet > total Current Assets
8430411
Quarters > 1 > balance Sheet > property Plant Equipment
1156277
Quarters > 1 > balance Sheet > total Assets
13035663
Quarters > 1 > balance Sheet > payables
885050
Quarters > 1 > balance Sheet > short Term Debt
472390
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
2811455
Quarters > 1 > balance Sheet > equity
10459986
Quarters > 1 > cash Flow > net Income
-3336120
Quarters > 1 > cash Flow > depreciation
118675
Quarters > 1 > cash Flow > change In Working Capital
76706
Quarters > 1 > cash Flow > cash From Operations
-3185035
Quarters > 1 > cash Flow > capital Expenditures
185319
Quarters > 1 > cash Flow > cash From Investing
-185319
Quarters > 1 > cash Flow > cash From Financing
899249
Quarters > 1 > cash Flow > net Change In Cash
-2471105
Quarters > 1 > ratios > PE
-15.353797841729053
Quarters > 1 > ratios > PB
0.4220831786964151
Quarters > 1 > ratios > ROE
-260.26424891964484
Quarters > 1 > ratios > ROA
-208.83942765320032
Quarters > 1 > ratios > FCF
-3370354
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-3.4273369033551835
Quarters > 1 > health Score
34
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
1196617
Quarters > 2 > income Statement > cost Of Revenue
512510
Quarters > 2 > income Statement > gross Profit
684107
Quarters > 2 > income Statement > operating Expenses
3648108
Quarters > 2 > income Statement > operating Income
-2964000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-2668713
Quarters > 2 > income Statement > net Income
-2639412
Quarters > 2 > income Statement > eps
-0.08374071639200414
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
31518861
Quarters > 2 > income Statement > income Tax Expense
14787922
Quarters > 2 > income Statement > EBITDA
-2905421
Quarters > 2 > income Statement > operating Margin
-247.69830279863982
Quarters > 2 > income Statement > total Other Income Expense Net
295288
Quarters > 2 > balance Sheet > cash
9294365
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
911502
Quarters > 2 > balance Sheet > inventories
468580
Quarters > 2 > balance Sheet > total Current Assets
11275955
Quarters > 2 > balance Sheet > property Plant Equipment
1245771
Quarters > 2 > balance Sheet > total Assets
15970701
Quarters > 2 > balance Sheet > payables
1233765
Quarters > 2 > balance Sheet > short Term Debt
558426
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
3421056
Quarters > 2 > balance Sheet > equity
12753478
Quarters > 2 > cash Flow > net Income
-2668713
Quarters > 2 > cash Flow > depreciation
58580
Quarters > 2 > cash Flow > change In Working Capital
-513926
Quarters > 2 > cash Flow > cash From Operations
-3326074
Quarters > 2 > cash Flow > capital Expenditures
116879
Quarters > 2 > cash Flow > cash From Investing
-116879
Quarters > 2 > cash Flow > cash From Financing
6306223
Quarters > 2 > cash Flow > net Change In Cash
2863270
Quarters > 2 > ratios > PE
-0.08374071639200414
Quarters > 2 > ratios > PB
6.153769496446381
Quarters > 2 > ratios > ROE
-20.695625146332635
Quarters > 2 > ratios > ROA
-16.526588281879423
Quarters > 2 > ratios > FCF
-3442953
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-2.877238916044148
Quarters > 2 > health Score
26
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
813107
Quarters > 3 > income Statement > cost Of Revenue
568208
Quarters > 3 > income Statement > gross Profit
244899
Quarters > 3 > income Statement > operating Expenses
3516154
Quarters > 3 > income Statement > operating Income
-3271255
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-3313743
Quarters > 3 > income Statement > net Income
-3296743
Quarters > 3 > income Statement > eps
-0.18581109795245795
Quarters > 3 > income Statement > dividends Per Share
155330
Quarters > 3 > income Statement > shares Outstanding
17742444
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-3194270
Quarters > 3 > income Statement > operating Margin
-402.31543941941214
Quarters > 3 > income Statement > total Other Income Expense Net
-42488
Quarters > 3 > balance Sheet > cash
6431095
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
362013
Quarters > 3 > balance Sheet > inventories
438592
Quarters > 3 > balance Sheet > total Current Assets
8047670
Quarters > 3 > balance Sheet > property Plant Equipment
1292395
Quarters > 3 > balance Sheet > total Assets
12789040
Quarters > 3 > balance Sheet > payables
1165727
Quarters > 3 > balance Sheet > short Term Debt
545912
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
3820955
Quarters > 3 > balance Sheet > equity
9142617
Quarters > 3 > cash Flow > net Income
-3296743
Quarters > 3 > cash Flow > depreciation
76985
Quarters > 3 > cash Flow > change In Working Capital
-193680
Quarters > 3 > cash Flow > cash From Operations
-3249065
Quarters > 3 > cash Flow > capital Expenditures
371250
Quarters > 3 > cash Flow > cash From Investing
-371250
Quarters > 3 > cash Flow > cash From Financing
-390721
Quarters > 3 > cash Flow > net Change In Cash
-4011036
Quarters > 3 > ratios > PE
-0.18581109795245795
Quarters > 3 > ratios > PB
4.832170653107311
Quarters > 3 > ratios > ROE
-36.05907367660704
Quarters > 3 > ratios > ROA
-25.777876994676692
Quarters > 3 > ratios > FCF
-3620315
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-4.452445988043394
Quarters > 3 > health Score
30
Valuation > metrics > PE
-6.897270715257212
Valuation > metrics > PB
0.19611862085146742
Valuation > final Score
70
Valuation > verdict
80.4% Undervalued
Profitability > metrics > ROE
-54.32462732190597
Profitability > metrics > ROA
-70.09116520415527
Profitability > metrics > Net Margin
-12.961411727602146
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.40573830083243284
Risk > metrics > Interest Coverage
-114.7223602484472
Risk > final Score
-399
Risk > verdict
High
Liquidity > metrics > Current Ratio
5.930391229315965
Liquidity > metrics > Quick Ratio
5.573525910223966
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
20
Prev Valuations > 2
31.67829346892689
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
-57
Prev Risks > 1
10
Prev Risks > 2
-50
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-16T22:24:48.935Z
Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. The company was founded in 1983 and is headquartered in Stony Brook, New York.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACan APDN stock resist market sell offs - Trade Volume Summary & Technical Entry and Exit Alerts DonanımHaber
Read more →Will APDN stock maintain dividend yield - 2025 Stock Rankings & Weekly Chart Analysis and Trade Guides DonanımHaber
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
HOLD
Target Price:
$1.5
Analyst Picks
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 6.42% of the total shares of Applied DNA Sciences Inc
1.
Anson Funds Management LP(3.6011%)
since
2025/06/30
2.
Sabby Management LLC(1.8858%)
since
2025/06/30
3.
UBS Group AG(0.8997%)
since
2025/06/30
4.
Tower Research Capital LLC(0.0172%)
since
2025/06/30
5.
SBI Securities Co Ltd(0.0113%)
since
2025/06/30
6.
BlackRock Inc(0.0003%)
since
2025/06/30
7.
Advisor Group Holdings, Inc.(0.0003%)
since
2025/06/30
8.
Bank of America Corp(0.0003%)
since
2025/06/30
9.
Morgan Stanley - Brokerage Accounts(0.0002%)
since
2025/06/30
10.
Wells Fargo & Co(0.0002%)
since
2025/06/30
11.
Mccormack Advisors International(0.0002%)
since
2025/06/30
12.
Wealth Preservation Advisors(0.0001%)
since
2025/06/30
13.
Westside Investment Management, Inc.(0.0001%)
since
2025/06/30
14.
Natixis SA(0.0001%)
since
2025/06/30
15.
Activest Wealth Management(0.0001%)
since
2025/06/30
16.
Royal Bank of Canada(0%)
since
2025/03/31
17.
Goldman Sachs Group Inc(0%)
since
2025/03/31
18.
Connective Capital Management LLC(0%)
since
2025/03/31
19.
PFG Investments, LLC(0%)
since
2025/06/30
20.
Jane Street Group LLC(0%)
since
2025/03/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.